
RESEARCH COMMUNICATION

Glutathione S-Transferase P1 Genotypes, Genetic Susceptibility and Outcome of Therapy in Thai Childhood Acute Lymphoblastic Leukemia

Jiraporn Gatedee¹, Samart Pakakassama², Sunsiree Muangman¹, Wanida Pongstaporn^{1,3*}

Abstract

Glutathione S-transferases (GSTs) are enzymes that involved in bio- transformation by conjugation of electrophilic compounds to glutathione. Polymorphisms within genes that encode GSTs may affect the function of the enzymes. Polymorphisms of GSTP1 at codon 105 residue forms *GSTP1* active site for binding of hydrophobic electrophiles, and the Ile-Val substitution affect substrate specific catalytic activity of this enzyme and may associate with susceptibility to malignant human disease, especially acute lymphoblastic leukemia (ALL), which is the most common leukemia in children younger than 15 years old. Genetic polymorphisms within the *GSTP1* gene of childhood ALL patients were studied. In addition, the association of genetic polymorphism of *GSTP1* and genetic susceptibility of acute lymphoblastic leukemia (ALL) was also determined using Chi-square and Odds ratio. PCR-RFLP was used to study genetic polymorphism of *GSTP1* in 100 ALL patients and 100 healthy individuals. The results show that there is no statistically significant association between each genotypes and genetic susceptibility of acute lymphoblastic leukemia (ALL) (OR=0.92, P-value=0.886). Moreover, there is no statistically significant association between each genotypes and demographic data of acute lymphoblastic leukemia (ALL). However, there are 2 cases of ALL with BM relapse show the polymorphic genotypes of *GSTP1*. It may suggest that *GSTP1*V105* may be involved in relapse of ALL.

Keywords: Acute lymphoblastic leukemia (ALL) - glutathione S-transferase (GST) - GSTP1

Asian Pacific J Cancer Prev, 8, 294-296

Introduction

Glutathione S-transferases (GSTs) are major phase II detoxifying enzymes and are able to perform a wide variety of functions. Phase II enzymes catalyze conjugation of activated xenobiotics to an endogenous water soluble substrate, such as glutathione (GSH), UDP-glucuronic acid or glycine (Miller et al., 1999).

The GSTs comprises a complex and widespread enzyme superfamily that has been subdivided into eight classes (Strange et al., 2001). *GSTP1* codes for enzyme glutathione S-transferase pi and is located on chromosome 11q13. It is also subject to polymorphic variation (Hayes and Pulford, 1995). Codon 105 residues from part of the *GSTP1* active site for binding of hydrophobic electrophiles and the Ile-Val substitution affect substrate-specific catalytic activity and thermal stability of the encoded protein (Fritz, 2005). Human *GSTP1* has been shown to catalyze the isomerization of 13-cisretinoic acid to all-trans-retinoic acid (Fukai et al., 1992). With this reason, *GSTP1* is mostly studied for the susceptibility of acute myeloid leukemia (Allan et al., 2001). Previous studies that

examined the relationship between *GSTP1* genotype and etiology and outcome of therapy in childhood acute lymphoblastic leukemia (ALL) are still controversial (Davies et al., 2002).

There are still no reports of *GSTP1* genotypes in Thai childhood ALL. Therefore, our study of 100 Thai children with ALL, was to provide an additional and more definitive data to be a preliminary report of *GSTP1* genotypes in Thai childhood ALL. Furthermore, an association study between the polymorphism of *GSTP1* and clinical outcome was also examined.

Materials and Methods

Specimens

One hundred cases of children (43 females and 57 males) with a median age of 5 years (range, 10 months to 14 years 9 months) were diagnosed with ALL at the Department of Pediatrics, Faculty of Medicine Ramathibodi Hospital, Mahidol University. Patients were treated on risk-adapted chemotherapy regimens modified total XII protocol (Smith et al., 1996). This was

¹Faculty of Medical Technology, Rangsit University, Phaholyothin Rd, Pathumthani, ²Department of Pediatric Oncology, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Thailand *For Correspondence: E-mail: wpongstaporn@yahoo.com

Table1. The Sequences of GSTP1 primers

Primers	Sequences
FGSTP1	TCCCCAGTGACTGTGTGTTG
RGSTP1	GAAGCCCCTTTCTTTGTTCA

retrospective case-control study. Normal controls were 100 cases of Thai normal individuals who were healthy (45 females and 55 males) and complete blood counts were normal.

DNA isolation

Genomic DNA was extracted from peripheral blood obtained from subjects using salting out methods with some modification (Miler et al, 1998). Briefly, the pellet of WBC was incubated in lysis buffer (10 mM Tris HCl, pH 8.0, 400 mM NaCl, 2 mM EDTA), 200 µl of 10% Sodium Dodecyl Sulfate (SDS) and 10 mg/ml Proteinase K at 60° C for 3 hours. The solution mixture was mixed with 6M NaCl, shaken and centrifuged at 10,000g at 4°C for 10 minutes. DNA was precipitated by adding absolute ethanol and then washed 3 times with 70% ethanol. DNA pellet was then dissolved in TE buffer.

PCR Protocols

PCR was performed from the DNA isolated from 100 ALL patient blood and 100 normal control blood with GSTP1 primers as shown in Table 1. Amplification was carried out in 50 µl reaction mixture containing PCR buffer(10mM Tris-HCl, pH 9.0, 50mM KCl,1.5 mM MgCL₂), 200 µM of each dNTP, 1.5 mM MgCL₂, 1 Unit of *Taq* DNA polymerase (Pharmacia Biotech, USA), 20 µM of each primers and 100 ng of genomic DNA.. DNA amplification was performed in Gene Amp PCR system 9700 for 40 cycles. Each cycle consists of denaturation at 95°C for 1 min, annealing at 60°C for 1 min and extension at 72°C for 1 min. PCR products were electrophoresized in 2% agarose gel.

Genotyping of GSTP1 gene polymorphism

The A to G polymorphism in codon 105 of GSTP1 gene (AAT to GAT) created *Bsm*AI recognition cleavage site. Genotyping of *GSTP1* gene polymorphism was performed by PCR-RFLP. The PCR product from exon 4 was digested for 18 hrs with 10U of *Bsm*AI (Biolabs,France) and visualized in 2% agarose gel stained with ethidium bromide. The digested products reveal the presence of 3 different patterns; the A/A wide type homozygote, demonstrated a 224 bp fragment, the G/G polymorphic homozygote presented the expected 146 bp fragment and 78 bp fragment, whereas A/G heterozygote exhibited 224, 146 and 78 bp fragments, respectively.

Table 2. GSTP1 Allele Frequency in Childhood ALL Patients and Normal Controls

<i>GSTP1</i>	n	Genotype, n (%)		Gene frequency		OR, 95%CI	p	
		I105/I105	I105/V105	V105/V105	I105			V105
ALL	100	59	36	5	0.77	0.23	0.92 (0.52-1.62)	0.886
Control	100	61	37	2	0.80	0.20		

Statistical analysis

The differences in genotypes and allele frequencies between cases and controls were determined by using Chi-square test. Odds ratio (OR) and 95% confidence intervals (CI) were also included. The association between demographic data of ALL patients and distribution of *GSTP1* genotypes were determined by Pearson Chi-square statistic or Fisher exact test. (SPSS version 12.0 (SPSS, Inc., Chicago, IL.) was used for all statistical methods.

Results

Genotype distribution

GSTP1 distribution was assessed in 100 ALL childhood and 100 controls. The allele frequency of *GSTP1* polymorphism was 0.23 and 0.20 in ALL patients and controls, respectively. The genotype distribution was in Hardy-Weinberg equilibrium. There was no significant differences in genotype distribution of *GSTP1* between ALL patients and controls (c²=0.256, P=0.886) (Table 2).

GSTP1 and the association of risk classification

With the modern chemotherapy, ALL patients can be classified according to the high risk (white blood cell count ≥50,000/ml) and low risk or standard risk (white blood cell count <50,000/ml) (Smith et al, 1996).It was found that, there was no association between *GSTP1**V105 and the high risk group in ALL patients. (c²=0.11, P=0.918) (Table 3).

GSTP1 and the association of the age at diagnosis

There was no statistically significant difference between genotypes of *GSTP1* and (c² =0.21, P = 0.380) (Table 3).

Discussion

Human *GSTP1* has been shown to catalyse the isomerization of 13 cis retinoic acid which is associated with the pathogenesis of AML. In ALL, enhanced *GSTP1* expression was described in blast from childhood acute lymphoblastic leukemia (Den Boer et al, 1999). Therefore, it is interesting to study the association between *GSTP1**V105 polymorphism and risk of ALL. However, in this study, the results showed that there was no statistically significant association of *GSTP1**V105 polymorphism and ALL susceptibility. This was in accordance with meta-analysis of *GSTP1* in ALL, which found no association between *GSTP1**V105 polymorphism and ALL in most studies (Zheng and Honglin, 2005). From the result of demographic data, there was no statistically significant association between

Table 3. Demographic Data of ALL Patients and Distribution of GSTP1 Genotypes

Characteristic	Total patient n=100, (%)	GSTP1		P value
		I105	V105	
Sex:				
Male	58	39	20	0.536
Female	42	22	19	
Age (yrs):				
<2	17	10	7	0.380
3-4	27	15	12	
5-8	23	18	5	
>8	24	15	9	
Risk group:				
standard	62	43	19	0.918
high	38	23	15	
Immunophenotype:				
Early-pre B	21	14	7	0.768
Pre-B	55	33	22	
B-cell	1	-	1	
T-cell	13	9	4	

GSTP1*V105 polymorphism and demographic data, including age at diagnosis, immunophenotype and risk classification. However, GSTP1*V105 polymorphism was found in all 2 cases of ALL with BM relapse. It may suggest that GSTP1*V105 may be involved in relapse of ALL. This is in accordance with the previous report that GSTP1 polymorphism may be involved in relapse of ALL (Martin et al, 2000). Because of polymorphic site at codon 105 is the active site for catalytic property of enzyme GSTP1 (Fritz, 2005), therefore, it may alter the expression of GSTP1 which may involve in xenobiotic metabolism of chemotherapeutic agents. This is in accordance with the previous report which suggest that polymorphism in GSTP1 is associated with susceptibility to chemotherapy-induced leukemia (Davies 2002).

Acknowledgement

Some parts of the laboratory work were performed by the students in Faculty of Medical Technology, Rangsit University. Most of all, we appreciate in every cases of ALL patients whose provide us the blood specimens for DNA extraction. Finally, we also appreciate the Department of Biochemistry, Faculty of Science, Rangsit University for their help in providing a PCR machine and other apparatus.

References

- Allan JM, Christopher PW, Sara R, et al (2001). Polymorphism of glutathione S-transferase P1 is associated with susceptibility to chemotherapy induced leukemia. *Proc Natl Acad Sci USA*, **98**, 11592-7.
- Davies SM, Bhatia S, Ross JA (2002). Glutathione S-transferase genotype, genetic susceptibility and outcome of therapy in childhood acute lymphoblastic leukemia. *Blood*, **100**, 67-71.
- Den Boer ML, et al (1999). Different expression of glutathione S-transferase a, m a and p in childhood acute lymphoblastic and myeloid leukemia. *Br J Hematol*, **104**, 321-7.

- Fritz FP (2005). Glutathione S-transferase genotypes and cancer risk. *Cancer Letters*, **221**, 123-9.
- Fukai F, Ohtaki H, Ueda T, et al (1992). A possible role of glutathione S-transferase in rat ovary and testis. *J Clin Biochem Nutr*, **12**, 93-107.
- Hayes JD, Pulford DJ (1995). The glutathione S-transferase supergene family Regulation of GST and contribution of isoenzymes to cancer chemoprotection and drug resistance. *Crit Rev Biochem Mol Biol*, **30**, 445-600.
- Martin Stanulla, Martin Schrappe, Annette Müller Brechlin, et al (2000). Polymorphisms within glutathione S-transferase genes (GSTM1, GSTT1, GSTP1) and risk of relapse in childhood B-cell precursor acute lymphoblastic leukemia: a case-control study. *Blood*, **95**, 1222-8.
- Miler SA, Dykes DD, Polsky HF (1988). Simple salting out procedure for extracting DNA from human nucleated cells. *Nucleic Acid Res*, **16**, 1215.
- Miller DS, Ow KK, Paul CL, et al (1999). Detailed methylation analysis of the glutathione S-transferase pi (GSTP1) gene in prostate cancer. *Oncogene*, **18**, 1313-24.
- Smith M, Arthur D, Camitta B, et al (1996). Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. *J Clin Oncol*, **14**, 18-24.
- Strange RC, Spiteri MA, Ramachandran S, et al (2001). Glutathione-S-transferase family of enzymes. *Mutat Res*, **482**, 21-6.
- Zheng Ye, Honglin Song (2005). Glutathione S-transferase polymorphisms (GSTM1, GSTT1 and GSTP1) in acute leukemia: A systematic review and meta-analysis. *Eur J Cancer*, **41**, 980-9.